1887

Abstract

Broadly neutralizing antibodies (NAbs) such as those generated in chronic human immunodeficiency virus type 1 (HIV-1) infection are considered a key component for an effective HIV-1 vaccine. Here, we measured NAb responses using a panel of 25 Env-pseudotyped viruses, including clade B, C, A, CRF07_BC and CRF01_AE strains, against plasma samples from 103 subjects in a former plasma donor cohort in central China, who were infected with HIV-1 clade B′ for at least 10 years and naïve to antiretroviral therapy at the time of sampling. We found that 64 % of samples ( = 66) neutralized at least half of the viruses tested and 2 % ( = 2) neutralized all of the viruses, while 5 % ( = 5) neutralized none of the viruses tested. Strikingly, 29 % of plasma samples ( = 30) neutralized >80 % of the viral strains tested, indicating the presence of broadly reactive NAbs in these patients. When the magnitude (geometric mean ID titres, GMTs) or breadth of neutralization was assessed for correlation with CD4 count or plasma viral load, the only significant positive correlations were observed between viral load and neutralization magnitude ( = 0.2189,  = 0.0263) and between viral load and neutralization breadth ( = 0.1970,  = 0.0461). A moderate difference between progressors and long-term non-progressors was observed in both the breadth ( = 0.0316) and the potency ( = 0.0300). A significant difference was found in the GMTs between intra-clade and inter-clade strains (<0.001). Heat-map analysis based on -means clustering of plasma determined a statistically stable cluster of plasma with cross-reactive and potent neutralizing reactivity. These samples could provide physical biomaterials for further virological and serological studies from which useful insights into rational HIV-1 vaccine development and therapeutic design might be derived.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.043802-0
2012-10-01
2019-10-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/10/2267.html?itemId=/content/journal/jgv/10.1099/vir.0.043802-0&mimeType=html&fmt=ahah

References

  1. Baba T. W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L. A., Posner M. R., Katinger H.. & other authors ( 2000;). Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. . Nat Med 6:, 200–206. [CrossRef][PubMed]
    [Google Scholar]
  2. Binley J. M., Lybarger E. A., Crooks E. T., Seaman M. S., Gray E., Davis K. L., Decker J. M., Wycuff D., Harris L.. & other authors ( 2008;). Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. . J Virol 82:, 11651–11668. [CrossRef][PubMed]
    [Google Scholar]
  3. Burton D. R., Desrosiers R. C., Doms R. W., Koff W. C., Kwong P. D., Moore J. P., Nabel G. J., Sodroski J., Wilson I. A., Wyatt R. T.. ( 2004;). HIV vaccine design and the neutralizing antibody problem. . Nat Immunol 5:, 233–236. [CrossRef][PubMed]
    [Google Scholar]
  4. Doria-Rose N. A., Klein R. M., Manion M. M., O’Dell S., Phogat A., Chakrabarti B., Hallahan C. W., Migueles S. A., Wrammert J.. & other authors ( 2009;). Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. . J Virol 83:, 188–199. [CrossRef][PubMed]
    [Google Scholar]
  5. Doria-Rose N. A., Klein R. M., Daniels M. G., O’Dell S., Nason M., Lapedes A., Bhattacharya T., Migueles S. A., Wyatt R. T.. & other authors ( 2010;). Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. . J Virol 84:, 1631–1636. [CrossRef][PubMed]
    [Google Scholar]
  6. Ehrlich H. J., Müller M., Oh H. M., Tambyah P. A., Joukhadar C., Montomoli E., Fisher D., Berezuk G., Fritsch S.. & other authors ( 2008;). A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. . N Engl J Med 358:, 2573–2584. [CrossRef][PubMed]
    [Google Scholar]
  7. Galli G., Medini D., Borgogni E., Zedda L., Bardelli M., Malzone C., Nuti S., Tavarini S., Sammicheli C.. & other authors ( 2009;). Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. . Proc Natl Acad Sci U S A 106:, 3877–3882. [CrossRef][PubMed]
    [Google Scholar]
  8. Gray E. S., Taylor N., Wycuff D., Moore P. L., Tomaras G. D., Wibmer C. K., Puren A., DeCamp A., Gilbert P. B.. & other authors ( 2009;). Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. . J Virol 83:, 8925–8937. [CrossRef][PubMed]
    [Google Scholar]
  9. Gray E. S., Madiga M. C., Hermanus T., Moore P. L., Wibmer C. K., Tumba N. L., Werner L., Mlisana K., Sibeko S.. & other authors ( 2011;). The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. . J Virol 85:, 4828–4840. [CrossRef][PubMed]
    [Google Scholar]
  10. Hessell A. J., Rakasz E. G., Poignard P., Hangartner L., Landucci G., Forthal D. N., Koff W. C., Watkins D. I., Burton D. R.. ( 2009;). Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. . PLoS Pathog 5:, e1000433. [CrossRef][PubMed]
    [Google Scholar]
  11. Hoxie J. A.. ( 2010;). Toward an antibody-based HIV-1 vaccine. . Annu Rev Med 61:, 135–152. [CrossRef][PubMed]
    [Google Scholar]
  12. Kaufman J., Jing J.. ( 2002;). China and AIDS – the time to act is now. . Science 296:, 2339–2340. [CrossRef][PubMed]
    [Google Scholar]
  13. Kwong P. D., Doyle M. L., Casper D. J., Cicala C., Leavitt S. A., Majeed S., Steenbeke T. D., Venturi M., Chaiken I.. & other authors ( 2002;). HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. . Nature 420:, 678–682. [CrossRef][PubMed]
    [Google Scholar]
  14. Lakhashe S. K., Kulkarni S. S., Thakar M. R., Ghate M. V., Paranjape R. S.. ( 2007;). Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1. . Virology 359:, 295–301. [CrossRef][PubMed]
    [Google Scholar]
  15. Li M., Gao F., Mascola J. R., Stamatatos L., Polonis V. R., Koutsoukos M., Voss G., Goepfert P., Gilbert P.. & other authors ( 2005;). Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. . J Virol 79:, 10108–10125. [CrossRef][PubMed]
    [Google Scholar]
  16. Li M., Salazar-Gonzalez J. F., Derdeyn C. A., Morris L., Williamson C., Robinson J. E., Decker J. M., Li Y., Salazar M. G.. & other authors ( 2006;). Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. . J Virol 80:, 11776–11790. [CrossRef][PubMed]
    [Google Scholar]
  17. Li Y., Migueles S. A., Welcher B., Svehla K., Phogat A., Louder M. K., Wu X., Shaw G. M., Connors M.. & other authors ( 2007;). Broad HIV-1 neutralization mediated by CD4-binding site antibodies. . Nat Med 13:, 1032–1034. [CrossRef][PubMed]
    [Google Scholar]
  18. Long E. M., Rainwater S. M., Lavreys L., Mandaliya K., Overbaugh J.. ( 2002;). HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. . AIDS Res Hum Retroviruses 18:, 567–576. [CrossRef][PubMed]
    [Google Scholar]
  19. Lu S., Grimes Serrano J. M., Wang S.. ( 2010;). Polyvalent AIDS vaccines. . Curr HIV Res 8:, 622–629. [CrossRef][PubMed]
    [Google Scholar]
  20. Mahalanabis M., Jayaraman P., Miura T., Pereyra F., Chester E. M., Richardson B., Walker B., Haigwood N. L.. ( 2009;). Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. . J Virol 83:, 662–672. [CrossRef][PubMed]
    [Google Scholar]
  21. Mascola J. R., Montefiori D. C.. ( 2003;). HIV-1: nature’s master of disguise. . Nat Med 9:, 393–394. [CrossRef][PubMed]
    [Google Scholar]
  22. Mascola J. R., Montefiori D. C.. ( 2010;). The role of antibodies in HIV vaccines. . Annu Rev Immunol 28:, 413–444. [CrossRef][PubMed]
    [Google Scholar]
  23. Mascola J. R., Louder M. K., Surman S. R., Vancott T. C., Yu X. F., Bradac J., Porter K. R., Nelson K. E., Girard M.. & other authors ( 1996;). Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. . AIDS Res Hum Retroviruses 12:, 1319–1328. [CrossRef][PubMed]
    [Google Scholar]
  24. Mascola J. R., Stiegler G., VanCott T. C., Katinger H., Carpenter C. B., Hanson C. E., Beary H., Hayes D., Frankel S. S.. & other authors ( 2000;). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. . Nat Med 6:, 207–210. [CrossRef][PubMed]
    [Google Scholar]
  25. Mikell I., Sather D. N., Kalams S. A., Altfeld M., Alter G., Stamatatos L.. ( 2011;). Characteristics of the earliest cross-neutralizing antibody response to HIV-1. . PLoS Pathog 7:, e1001251. [CrossRef][PubMed]
    [Google Scholar]
  26. Moir S., Fauci A. S.. ( 2009;). B cells in HIV infection and disease. . Nat Rev Immunol 9:, 235–245. [CrossRef][PubMed]
    [Google Scholar]
  27. Montefiori D. C.. ( 2005;). Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. . Curr Protoc Immunol 64:, 12.11.1–12.11.17. [CrossRef][PubMed]
    [Google Scholar]
  28. Nair N., Gans H., Lew-Yasukawa L., Long-Wagar A. C., Arvin A., Griffin D. E.. ( 2007;). Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. . J Infect Dis 196:, 1339–1345. [CrossRef][PubMed]
    [Google Scholar]
  29. Ozaki D. A., Gao H., Todd C. A., Greene K. M., Montefiori D. C., Sarzotti-Kelsoe M.. ( 2012;). International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials. . PLoS ONE 7:, e30963. [CrossRef][PubMed]
    [Google Scholar]
  30. Parren P. W., Marx P. A., Hessell A. J., Luckay A., Harouse J., Cheng-Mayer C., Moore J. P., Burton D. R.. ( 2001;). Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. . J Virol 75:, 8340–8347. [CrossRef][PubMed]
    [Google Scholar]
  31. Phogat S., Wyatt R.. ( 2007;). Rational modifications of HIV-1 envelope glycoproteins for immunogen design. . Curr Pharm Des 13:, 213–227. [CrossRef][PubMed]
    [Google Scholar]
  32. Piantadosi A., Panteleeff D., Blish C. A., Baeten J. M., Jaoko W., McClelland R. S., Overbaugh J.. ( 2009;). Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. . J Virol 83:, 10269–10274. [CrossRef][PubMed]
    [Google Scholar]
  33. Platt E. J., Wehrly K., Kuhmann S. E., Chesebro B., Kabat D.. ( 1998;). Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. . J Virol 72:, 2855–2864.[PubMed]
    [Google Scholar]
  34. Poss M., Overbaugh J.. ( 1999;). Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. . J Virol 73:, 5255–5264.[PubMed]
    [Google Scholar]
  35. Sather D. N., Armann J., Ching L. K., Mavrantoni A., Sellhorn G., Caldwell Z., Yu X., Wood B., Self S.. & other authors ( 2009;). Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. . J Virol 83:, 757–769. [CrossRef][PubMed]
    [Google Scholar]
  36. Scheid J. F., Mouquet H., Feldhahn N., Seaman M. S., Velinzon K., Pietzsch J., Ott R. G., Anthony R. M., Zebroski H.. & other authors ( 2009;). Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. . Nature 458:, 636–640. [CrossRef][PubMed]
    [Google Scholar]
  37. Schlereth B., Rose J. K., Buonocore L., ter Meulen V., Niewiesk S.. ( 2000;). Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. . J Virol 74:, 4652–4657. [CrossRef][PubMed]
    [Google Scholar]
  38. Seaman M. S., Janes H., Hawkins N., Grandpre L. E., Devoy C., Giri A., Coffey R. T., Harris L., Wood B.. & other authors ( 2010;). Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. . J Virol 84:, 1439–1452. [CrossRef][PubMed]
    [Google Scholar]
  39. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M. W., Martin M. A.. ( 1999;). Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. . Nat Med 5:, 204–210. [CrossRef][PubMed]
    [Google Scholar]
  40. Simek M. D., Rida W., Priddy F. H., Pung P., Carrow E., Laufer D. S., Lehrman J. K., Boaz M., Tarragona-Fiol T.. & other authors ( 2009;). Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. . J Virol 83:, 7337–7348. [CrossRef][PubMed]
    [Google Scholar]
  41. Su B., Liu L., Wang F., Gui X., Zhao M., Tien P., Zhang L., Chen Z.. ( 2003;). HIV-1 subtype B′ dictates the AIDS epidemic among paid blood donors in the Henan and Hubei provinces of China. . AIDS 17:, 2515–2520. [CrossRef][PubMed]
    [Google Scholar]
  42. Tibshirani R., Walther G., Hastie T.. ( 2001;). Estimating the number of clusters in a data set via the gap statistic. . J R Stat Soc B 63:, 411–423. [CrossRef]
    [Google Scholar]
  43. Todd C. A., Greene K. M., Yu X., Ozaki D. A., Gao H., Huang Y., Wang M., Li G., Brown R.. & other authors ( 2012;). Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. . J Immunol Methods 375:, 57–67. [CrossRef][PubMed]
    [Google Scholar]
  44. Tomaras G. D., Binley J. M., Gray E. S., Crooks E. T., Osawa K., Moore P. L., Tumba N., Tong T., Shen X.. & other authors ( 2011;). Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. . J Virol 85:, 11502–11519. [CrossRef][PubMed]
    [Google Scholar]
  45. Trkola A., Kuster H., Rusert P., Joos B., Fischer M., Leemann C., Manrique A., Huber M., Rehr M.. & other authors ( 2005;). Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. . Nat Med 11:, 615–622. [CrossRef][PubMed]
    [Google Scholar]
  46. van Gils M. J., Bunnik E. M., Burger J. A., Jacob Y., Schweighardt B., Wrin T., Schuitemaker H.. ( 2010a;). Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. . J Virol 84:, 3576–3585. [CrossRef][PubMed]
    [Google Scholar]
  47. van Gils M. J., Edo-Matas D., Schweighardt B., Wrin T., Schuitemaker H.. ( 2010b;). High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity. . J Gen Virol 91:, 250–258. [CrossRef][PubMed]
    [Google Scholar]
  48. Veazey R. S., Shattock R. J., Pope M., Kirijan J. C., Jones J., Hu Q., Ketas T., Marx P. A., Klasse P. J.. & other authors ( 2003;). Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. . Nat Med 9:, 343–346. [CrossRef][PubMed]
    [Google Scholar]
  49. Wang S. H., Xing H., Wang J. J., Su B., Chen X., Quan Y., Zhao Q. B., Ruan Y. H., Xu J. Q.. & other authors ( 2007;). Sequence analysis of gag and env genes of HIV type 1 circulating in former blood donors of Fuyang city, Anhui province. . Zhonghua Yi Xue Za Zhi 87:, 1535–1539 (in Chinese). [PubMed]
    [Google Scholar]
  50. Wei X., Decker J. M., Liu H., Zhang Z., Arani R. B., Kilby J. M., Saag M. S., Wu X., Shaw G. M., Kappes J. C.. ( 2002;). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. . Antimicrob Agents Chemother 46:, 1896–1905. [CrossRef][PubMed]
    [Google Scholar]
  51. Wu X., Yang Z. Y., Li Y., Hogerkorp C. M., Schief W. R., Seaman M. S., Zhou T., Schmidt S. D., Wu L.. & other authors ( 2010;). Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. . Science 329:, 856–861. [CrossRef][PubMed]
    [Google Scholar]
  52. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., Chen X., Longo N. S., Louder M.. & other authors ( 2011;). Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. . Science 333:, 1593–1602. [CrossRef][PubMed]
    [Google Scholar]
  53. Xu J. Q., Wang J. J., Han L. F., Xu C., Ruan Y. H., Xu Z. H., Chen X., Liu Z. D., Wang J.. & other authors ( 2006;). Epidemiology, clinical and laboratory characteristics of currently alive HIV-1 infected former blood donors naive to antiretroviral therapy in Anhui Province, China. . Chin Med J (Engl) 119:, 1941–1948.[PubMed]
    [Google Scholar]
  54. Zhang X., Xu J., Peng H., Ma Y., Han L., Ruan Y., Su B., Wang N., Shao Y.. ( 2008;). HCV coinfection associated with slower disease progression in HIV-infected former plasma donors naïve to ART. . PLoS ONE 3:, e3992. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.043802-0
Loading
/content/journal/jgv/10.1099/vir.0.043802-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error